Last updated on November 2019

BAX 855 Previously Untreated Patient (PUP)

Brief description of study

The purpose of this study is to investigate safety, immunogenicity and hemostatic efficacy of PEGylated recombinant FVIII (BAX 855) in previously untreated patients (PUPs) < 6 years of age with severe hemophilia A (baseline FVIII level < 1%) and < 3 EDs to ADVATE, BAX 855 or plasma transfusion.

Clinical Study Identifier: NCT02615691

Find a site near you

Start Over

Helsinki Univ Hospital

Helsinki, Finland
  Connect »